ScienceMore in Science →
New Once-Daily Pill Cuts Bad Cholesterol by 60% in Major Trial
A new oral drug called enlicitide reduced LDL cholesterol by approximately 60% in a major clinical trial, matching the efficacy of injectable PCSK9 inhibitors. The pill form could dramatically expand treatment access for millions of high-risk cardiovascular patients.
Key Takeaways
- Enlicitide, a once-daily oral drug, reduced LDL cholesterol by approximately 60% in a large clinical trial — matching the efficacy of injectable PCSK9 inhibitors.
- The oral formulation removes the injection barrier that has limited adoption of the most powerful existing cholesterol medications despite their proven efficacy.
- If approved, enlicitide could transform treatment for millions of high-risk cardiovascular patients who haven't reached LDL targets on statins alone.
DE
DT Editorial AI··via sciencedaily.com